Chris Schott is ranked #2317 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Chris Schott (J.P. Morgan) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Chris Schott's stock ratings?

About 36% of Chris's ratings were profitable over a one-year hold, with an average return of -7.2% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Chris Schott

JPM

Chris Schott

J.P. Morgan

Wall Street Analyst

★★☆☆☆

#2317

on 13Foresight · ranked by our own returns

32%

Success Rate

-12.3%

Average Return

9 of 28 calls profitable · -24.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 32% of Chris Schott's ratings turned a profit when each position was held for 2 year — averaging -12.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

80 Buy 36 Hold 3 Sell

Chris's Stock Coverage 27 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
TEVA Teva Pharmaceutical	Jun 15, 2026	BUY	Buy -6.8% avg upside 39 analysts	—	-3.4%
LLY Eli Lilly & Co	Jun 09, 2026	BUY	Strong Buy -10.5% avg upside 47 analysts	—	-4.0%
GILD Gilead Sciences	Jun 08, 2026	BUY	Strong Buy -4.8% avg upside 66 analysts	—	-2.8%
PFE Pfizer	Jun 01, 2026	HOLD	Buy +34.1% avg upside 45 analysts	$30.00 18.99% Upside	-1.6%
REGN Regeneron	May 18, 2026	BUY	Strong Buy +26.9% avg upside 57 analysts	$850.00 39.27% Upside	-3.3%
VTRS Viatris	May 08, 2026	HOLD	Buy +48.2% avg upside 21 analysts	$18.00 17.02% Upside	-7.8%
ZTS Zoetis	May 08, 2026	BUY	Buy +71.4% avg upside 22 analysts	$130.00 65.07% Upside	-6.7%
RPRX Royalty Pharma	May 07, 2026	BUY	Strong Buy +4.2% avg upside 15 analysts	$58.00 9.52% Upside	+7.4%
ELAN Elanco Animal Health	May 07, 2026	BUY	Strong Buy +24.1% avg upside 18 analysts	$30.00 23.85% Upside	+0.9%
BIIB Biogen	Apr 24, 2026	HOLD	Strong Buy +25.1% avg upside 51 analysts	$185.00 5.95% Downside	+7.8%
JNJ Johnson & Johnson	Apr 15, 2026	HOLD	Strong Buy -3.6% avg upside 36 analysts	$260.00 13.79% Upside	-0.9%
ABBV AbbVie	Apr 07, 2026	BUY	Buy +2.8% avg upside 43 analysts	$260.00 20.03% Upside	+8.1%
MRK Merck & Company	Apr 06, 2026	BUY	Strong Buy +10.7% avg upside 43 analysts	$135.00 18.56% Upside	-3.8%
AMRX Amneal Pharmaceuticals	Mar 02, 2026	BUY	Strong Buy +5.6% avg upside 18 analysts	$18.00 11.10% Upside	+18.2%
PRGO Perrigo Company	Feb 27, 2026	HOLD	Buy +565.5% avg upside 20 analysts	$15.00 46.42% Upside	-19.4%
OGN Organon	Feb 13, 2026	SELL	Sell +10.6% avg upside 9 analysts	$11.00 18.09% Downside	-82.3%
BMY Bristol-Myers Squibb	Jan 28, 2026	BUY	Buy +9.1% avg upside 42 analysts	$65.00 20.42% Upside	+2.3%
IDXX Idexx Laboratories	Nov 03, 2025	BUY	Buy +29.2% avg upside 17 analysts	$775.00 37.96% Upside	-22.4%
AMGN Amgen	Sep 16, 2025	HOLD	Buy -11.6% avg upside 57 analysts	$300.00 11.19% Downside	+30.1%
CHRS Coherus Biosciences	May 25, 2023	HOLD	Buy +748.3% avg upside 18 analysts	$8.00 440.50% Upside	-82.4%
TSE:BHC Bausch Health Companies	Jul 28, 2022	HOLD	Buy +783.6% avg upside 29 analysts	—	·
TXMD TherapeuticsMD	May 19, 2020	HOLD	Buy +220.5% avg upside 8 analysts	—	-95.9%
DE:MRK Merck KGaA	Mar 09, 2020	BUY	Buy +2.1% avg upside 32 analysts	$85.51 35.78% Downside	·
PCRX Pacira Pharmaceuticals	Feb 20, 2020	HOLD	Buy +74.3% avg upside 21 analysts	$54.00 141.89% Upside	+27.8%
SNNAQ Sienna Biopharmaceuticals	May 13, 2019	HOLD	Buy +299999899.9% avg upside 2 analysts	—	-33.3%
KALA KALA BIO	Nov 17, 2017	BUY	Strong Buy +5814.9% avg upside 9 analysts	$35.00 869.51% Upside	-80.3%
AMRN Amarin	Oct 17, 2013	HOLD	Buy -47.2% avg upside 18 analysts	—	·

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Chris Schott — Frequently Asked Questions

How accurate are Chris Schott's stock ratings?

Based on the calls 13Foresight could measure, about 36% of Chris's ratings were profitable over a one-year hold, with an average return of -7.2% per rating, or -15.7% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Chris ranked on 13Foresight?

Chris Schott is currently ranked #2317 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Chris cover?

Chris most recently has ratings on TEVA, LLY, GILD, PFE, REGN, VTRS, ZTS, RPRX, ELAN, BIIB, JNJ, ABBV and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!